Figure 3. Analysis of Treatment Effect on the Primary Efficacy Outcome Across Subgroups.

The primary efficacy outcome was recurrent stroke, which included stroke of ischemic, hemorrhagic, or unknown type. All subgroup analyses were prespecified. NT-proBNP indicates N-terminal pro-B-type natriuretic peptide and PTFV₁, P-wave terminal force in lead V₁. No statistically significant interactions were found at a Bonferroni-corrected P value threshold of .007, including when modeling the atrial cardiopathy biomarkers as continuous variables (P values for interaction: .68 [NT-proBNP], .35 [PTFV₁], and .11 [left atrial diameter index] for treatment).